EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY 4.0

Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Alexander J Blood, Ozan Unlu, John W Ostrominski, Shahzad Hassan iD, Hunter Nichols, Samantha Subramaniam, Daniel Gabovitch, Jacqueline Chasse, Marian McPartlin, Christian Figueroa, Emma Collins, Megan Twining und 5 weitere

Clinical Cardiology · 2026-02 · 49 (2)

DOI: 10.1002/clc.70222 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Cardiology, online erschienen am 06.02.2026. Verfasst von Alexander J Blood und 16 weiteren Autor:innen. Beteiligte Einrichtung: Accelerator for Clinical Transformation, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Cardiovascular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Eli Lilly and Company (Lilly), The National Heart Lung and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite overwhelming evidence of clinical benefit for patients with heart failure (HF), the uptake of guideline‐directed medical therapies (GDMT) has been slow. Collaborative approaches are critically needed to improve alignment between evidence and clinical practice. Many strategies proposed to improve GDMT implementation have been either ineffective or too resource‐intensive to implement at scale across different practice contexts. Furthermore, most existing approaches focus primarily on patients with HF and reduced EF, despite growing evidence for effective pharmacologic therapy in those with HF and mildly reduced or preserved ejection fraction (HFpEF). Hypothesis Based on this experience, we designed the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT‐HF) study (NCT05734690).

Methods

This is a pragmatic, randomized, open‐label intervention trial to compare a comprehensive, remote, navigator‐led, algorithm‐driven strategy for optimization of GDMT prescribing in patients with HF across the full spectrum of ejection fraction with a control intervention focused on patient and provider education regarding the importance of GDMT optimization.

Results

The primary efficacy endpoint of the study is the proportion of patients receiving optimal HF treatment at 3 months. Additional outcomes of interest include the proportion of patients with optimal HF therapy at 6 months and 12 months as well as health resource utilization, including hospitalizations and deaths.

Conclusions

COPILOT‐HF will evaluate the effectiveness of an early implementation of a remote pharmacist‐led medication titration strategy across the HF spectrum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeCardiovascular AgentsHumansTreatment OutcomePractice Guidelines as TopicTime FactorsFemaleGuideline Adherence

Stichwörter der Autor:innen

digital healthguideline‐directed medical therapyheart failureremote health

Substanzen

Cardiovascular Agents

Autor:innen und Institutionen

  • Accelerator for Clinical Transformation, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Shahzad Hassan, Christopher P Cannon

Förderung

  • Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)
  • Eli Lilly and Company (Lilly)
  • The National Heart Lung and Blood Institute
  • The National Institutes of Health
  • Boehringer Ingelheim

Zitieren

APA

Blood, A. J., Unlu, O., Ostrominski, J. W., Hassan, S., Nichols, H., Subramaniam, S., Gabovitch, D., Chasse, J., McPartlin, M., Figueroa, C., Collins, E., Twining, M., Varugheese, M., Wagholikar, K., Cannon, C. P., Desai, A. S., & Scirica, B. M. (2026). Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure. Clinical Cardiology, 49(2). https://doi.org/10.1002/clc.70222

Vancouver

Blood AJ, Unlu O, Ostrominski JW, Hassan S, Nichols H, Subramaniam S, et al. Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure. Clinical Cardiology. 2026;49(2). doi:10.1002/clc.70222

BibTeX
@article{Blood2026,
  author = {Blood, Alexander J and Unlu, Ozan and Ostrominski, John W and Hassan, Shahzad and Nichols, Hunter and Subramaniam, Samantha and Gabovitch, Daniel and Chasse, Jacqueline and McPartlin, Marian and Figueroa, Christian and Collins, Emma and Twining, Megan and Varugheese, Matthew and Wagholikar, Kavishwar and Cannon, Christopher P and Desai, Akshay S and Scirica, Benjamin M},
  title = {Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure},
  journal = {Clinical Cardiology},
  year = {2026},
  volume = {49},
  number = {2},
  doi = {10.1002/clc.70222}
}
Kostenlos starten →